PATIENT JOURNEY

This tool is to help potential participants better understand what they can expect during the MASTERS-2 study.

1) Get Diagnosed with an Ischemic Stroke

You must be diagnosed with an ischemic stroke as soon as possible to be eligible for study participation.

2) Review & Sign Informed Consent

The Informed Consent Form (ICF) explains what you can expect from the study. You (or your legal representative) must sign it before you can participate.

3) Confirm Study Eligibility through Screening

A study doctor will perform any required additional assessments to ensure you are able to participate in the study.

4) Receive MultiStem® (or placebo) through an IV

Within 18-36 hours after your stroke symptoms started, you will be given either MultiStem cells or placebo through an IV. The infusion will last about 2 hours.

5) Complete Follow-Up Period

After the infusion with the investigational product, the total follow-up period will last approximately 1 year and will include 4 additional in-person study site visits.

6) Receive Remote Follow-Ups by Phone

You will be contacted by phone or web conference in between the in-person study site visits.

MASTERS-2

opening the window for stroke treatment

PATIENT **JOURNEY**

This tool is to help potential study participants better understand what they can expect during the MASTERS-2 study.

Get Diagnosed with an Ischemic Stroke

To be eligible for the MASTERS-2 study, your diagnosis must confirm that you have experienced an ischemic stroke in the last 28 hours.

Review & Sign Informed Consent

If you decide to participate in this study, you (or your legal representative) will first be asked to read and sign a Participant Informed Consent Form. This form explains the study and what you can expect in more detail. No study-related procedures can begin until this form is signed.

Confirm Study Eligibility through Screening

Assessments may include a brain scan, stroke assessment, blood test, heart test, and physical exam. In some cases, you may have already received these procedures when you were first admitted to the hospital, and before knowing about this clinical study, as part of routine (standard of care) treatment for stroke. This information may be used to help decide if you are eligible for the study.

Receive MultiStem® (or placebo) through an IV

Within 18-36 hours after your stroke symptoms started, you will be randomly assigned to be given either MultiStem cells or placebo through an IV. Half of study participants will receive MultiStem, cells and half will receive placebo, which has no active ingredients. Neither you nor the study team will know which investigational product you are given. The infusion of the investigational product will last about 2 hours.

Complete Follow-Up Period

During the hospitalization following your stroke, the study staff will monitor your health and symptoms. You will receive several evaluations including blood tests, physical exams, and assessments to determine if there has been any change in your stroke severity and abilities to complete routine tasks. You and your doctor will determine when you are released from the hospital.

You will have 4 additional visits at the study site throughout the rest of the year (1 month, 3 months, 6 months, and 1 year). At these visits, study staff will ask about your symptoms and perform repeat assessments to determine any change in disability resulting from your stroke.

Receive Remote Follow-Ups by Phone

During the phone or web conferences, you will be asked how you are feeling, and the study staff will discuss any rehabilitation activities you have participated in and any recent hospitalizations.

Please Note:

Your participation in this study is voluntary. You may discontinue your involvement at any time. If you decide to leave the study before the last study visit, tell the study doctor and follow his/her instructions. It is important that you come in to the study site for a final visit.

MASTERS-2

opening the window for stroke treatment